“Difficult” Bioequivalence Issues Make Limited Progress At Advisory Cmte.
Executive Summary
If the July 23 meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee is any indication, FDA appears years away from changing approval standards for generics of drugs with complex dosage forms.
You may also be interested in...
Respiratory Generics: Big Potential But A Tough Market To Crack
With GlaxoSmithKline's blockbuster asthma drug Advair facing patent expiration later this year, generic drug makers like Teva and Sandoz are looking to pounce on the opportunity
Respiratory Generics: Big Potential But A Tough Market To Crack
With GlaxoSmithKline's blockbuster asthma drug Advair facing patent expiration later this year, generic drug makers like Teva and Sandoz are looking to pounce on the opportunity
Generic Approval Standards For Vancomycin Tightened In FDA Draft Guidance
FDA has tightened approval standards for generic oral vancomycin, but appears to have left enough latitude in bioequivalence testing requirements to not greatly impede generic competition